Company
UK firm commercialising drug discovery and development programs
Every investor coverage indicates participated in a round Molecule to Medicine (MTM) raised.
Companies Molecule to Medicine (MTM) acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Molecule to Medicine (MTM). Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Queensland drug developer Lucia Bio added $2 million to its seed round from UniQuest Extension Fund and Uniseed-managed funds, bringing its overall raise to $3 million ahead of a planned Series A.
Pathios Therapeutics has dosed the first patient in a Phase 1/2 trial of its GPR65 inhibitor PTT-4256, run by its Australian team; the company also cites US$58M raised to date.